AR062482A1 - Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados - Google Patents
Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionadosInfo
- Publication number
- AR062482A1 AR062482A1 ARP070103727A ARP070103727A AR062482A1 AR 062482 A1 AR062482 A1 AR 062482A1 AR P070103727 A ARP070103727 A AR P070103727A AR P070103727 A ARP070103727 A AR P070103727A AR 062482 A1 AR062482 A1 AR 062482A1
- Authority
- AR
- Argentina
- Prior art keywords
- hepatitis
- rna
- hcv
- individual
- ns5b
- Prior art date
Links
- WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 7
- 238000012512 characterization method Methods 0.000 title 1
- 230000010076 replication Effects 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 15
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 7
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 208000015181 infectious disease Diseases 0.000 abstract 4
- 108060004795 Methyltransferase Proteins 0.000 abstract 3
- 230000001419 dependent effect Effects 0.000 abstract 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Métodos para disminuir la frecuencia de aparicion, disminuir el nivel de resistencia y retardar la aparicion de una infeccion viral de hepatitis C resistente al tratamiento, mediante la administracion a un sujeto, ya sea en forma combinada o en serie, de un inhibidor de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C, por ejemplo, un benzofurano, tal como 5-ciclopropil-2-(4-fluorofenil)-6-[(2-hidroxietil)(metilsulfonil)amino]-N-metil-1-benzofuran-3-carboxamida (VHC-796), y al menos un agente anti-hepatitis C adicional, por ejemplo, un producto de ribavirina o un inmunomodulador, tal como un producto de interferon. Además se refiere a métodos para monitorear el curso de tratamiento de una infeccion viral de hepatitis C, métodos para monitorear y pronosticar una infeccion viral de hepatitis C, y métodos para identificar un individuo con menor probabilidad de responder a un tratamiento contra la hepatitis C viral. Estos métodos usan la secuencia y/o estructura de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C para identificar la aparicion de una infeccion viral de hepatitis C resistente al tratamiento, en particular una infeccion viral de hepatitis C resistente al tratamiento con benzofurano (por ejemplo, VHC-796). Reivindicacion 11: Un método para identificar un individuo con menor probabilidad de responder a un tratamiento contra la hepatitis C viral, que comprende: (a) determinar la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C en una muestra del individuo en un primer punto temporal; y (b) determinar la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C en una muestra del individuo en un segundo punto temporal, donde un cambio en la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C en la muestra del individuo en el segundo punto temporal, en comparacion con la secuencia o estructura de aminoácidos del bolsillo de union de VHC-796 de la polimerasa NS5B de ARN dependiente del ARN de la hepatitis C del individuo en el primer punto temporal, indica una menor probabilidad de que el individuo responda a un tratamiento contra la hepatitis C viral.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84035306P | 2006-08-25 | 2006-08-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR062482A1 true AR062482A1 (es) | 2008-11-12 |
Family
ID=39022157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070103727A AR062482A1 (es) | 2006-08-25 | 2007-08-22 | Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080182895A1 (es) |
| AR (1) | AR062482A1 (es) |
| AU (1) | AU2007286754A1 (es) |
| BR (1) | BRPI0715714A2 (es) |
| CA (1) | CA2659461A1 (es) |
| CL (1) | CL2007002447A1 (es) |
| PE (1) | PE20081215A1 (es) |
| TW (1) | TW200816990A (es) |
| WO (1) | WO2008024763A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044923A2 (en) * | 2004-10-18 | 2006-04-27 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis c infection |
| EP2101173A1 (en) * | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
| FR2933094A1 (fr) * | 2008-06-26 | 2010-01-01 | Univ Joseph Fourier | Mutations dans la proteine ns5b du vhc. |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CN104383541A (zh) | 2011-10-21 | 2015-03-04 | 艾伯维公司 | 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法 |
| DK2583680T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| DE102014219858B4 (de) | 2014-09-30 | 2021-09-23 | Aktiebolaget Skf | Kreuzgelenk |
| CA3022119A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| GB201704386D0 (en) * | 2017-03-20 | 2017-05-03 | Univ London Queen Mary | Method for identification of sofosbuvir resistant patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324212A (zh) * | 1998-09-25 | 2001-11-28 | 维洛药品公司 | 治疗或预防病毒感染及有关疾病的方法 |
| DE10030139A1 (de) * | 2000-06-20 | 2002-01-10 | Cmi Ag | Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae |
| RU2355700C9 (ru) * | 2000-07-21 | 2010-03-20 | Шеринг Корпорейшн | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с |
| WO2002048388A2 (en) * | 2000-10-25 | 2002-06-20 | Vincent Agnello | Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| AU2002232660A1 (en) * | 2000-12-15 | 2002-06-24 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| TW200400963A (en) * | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
| TW200400818A (en) * | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
| AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| US20050159345A1 (en) * | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
| US7842719B2 (en) * | 2002-10-31 | 2010-11-30 | Kemin Foods, L.C. | Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| JP4537315B2 (ja) * | 2002-11-01 | 2010-09-01 | バイロファーマ・インコーポレイテッド | ベンゾフラン化合物、組成物およびｃ型肝炎感染症および関連疾患の治療または予防方法 |
| KR20050088079A (ko) * | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
| CA2512713C (en) * | 2003-01-07 | 2012-03-13 | Kemin Pharma Europe, B.V.B.A. | Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses |
| JP2006524227A (ja) * | 2003-03-28 | 2006-10-26 | ファーマセット，インク． | フラビウイルス科ウイルス感染の治療のための化合物 |
| WO2005000308A2 (en) * | 2003-05-15 | 2005-01-06 | Rigel Pharmaceuticals, Inc. | Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
| PL1658302T3 (pl) * | 2003-07-25 | 2011-03-31 | Idenix Pharmaceuticals Inc | Analogi nukleozydów purynowych do leczenia chorób spowodowanych przez Flaviviridae obejmujących zapalenie wątroby typu C |
| TW200528459A (en) * | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| JP2005202801A (ja) * | 2004-01-16 | 2005-07-28 | Sharp Corp | 表示装置 |
| CA2571675A1 (en) * | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| US20060035848A1 (en) * | 2004-08-09 | 2006-02-16 | Zymetx, Inc. | Broad-spectrum inhibitor of viruses in the Flaviviridae family |
| TWM262874U (en) * | 2004-08-10 | 2005-04-21 | Starlink Electronics Corp | LGA terminal structure with changed circuit |
| JP2008514611A (ja) * | 2004-09-23 | 2008-05-08 | ワイス | Ｃ型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体 |
| US7754685B2 (en) * | 2005-09-30 | 2010-07-13 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection |
| EP1945623A2 (en) * | 2005-11-10 | 2008-07-23 | Wyeth a Corporation of the State of Delaware | Polymorphs of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and methods of making the same |
| US20070128270A1 (en) * | 2005-11-10 | 2007-06-07 | Wyeth | Pharmaceutical formulations containing 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide and method of making the same |
| EP1981523A2 (en) * | 2006-02-09 | 2008-10-22 | Schering Corporation | Novel hcv inhibitor combinations and methods |
| TW200815384A (en) * | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
-
2007
- 2007-08-21 US US11/842,312 patent/US20080182895A1/en not_active Abandoned
- 2007-08-21 CA CA002659461A patent/CA2659461A1/en not_active Abandoned
- 2007-08-21 BR BRPI0715714-2A2A patent/BRPI0715714A2/pt not_active Application Discontinuation
- 2007-08-21 AU AU2007286754A patent/AU2007286754A1/en not_active Abandoned
- 2007-08-21 WO PCT/US2007/076408 patent/WO2008024763A2/en active Application Filing
- 2007-08-22 AR ARP070103727A patent/AR062482A1/es unknown
- 2007-08-22 PE PE2007001141A patent/PE20081215A1/es not_active Application Discontinuation
- 2007-08-22 CL CL200702447A patent/CL2007002447A1/es unknown
- 2007-08-22 TW TW096131070A patent/TW200816990A/zh unknown
-
2009
- 2009-06-29 US US12/493,736 patent/US20100028922A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007286754A1 (en) | 2008-02-28 |
| CL2007002447A1 (es) | 2008-03-14 |
| PE20081215A1 (es) | 2008-10-22 |
| BRPI0715714A2 (pt) | 2014-03-11 |
| CA2659461A1 (en) | 2008-02-28 |
| TW200816990A (en) | 2008-04-16 |
| US20080182895A1 (en) | 2008-07-31 |
| WO2008024763A2 (en) | 2008-02-28 |
| WO2008024763A3 (en) | 2008-12-24 |
| US20100028922A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR062482A1 (es) | Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados | |
| Bai et al. | A paradoxical role for neutrophils in the pathogenesis of West Nile virus | |
| Davy et al. | White-nose syndrome is associated with increased replication of a naturally persisting coronaviruses in bats | |
| Chen et al. | ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment | |
| Dietz et al. | Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients | |
| Leung et al. | Ebolavirus VP35 is a multifunctional virulence factor | |
| GEP20247600B (en) | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| ES2572329A2 (es) | Combinacion de al menos dos agentes antivirales de accion directa y ribavirina pero no interferon, para uso en el tratamientodel vhc | |
| CL2009000305A1 (es) | Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv). | |
| Wang et al. | Influenza A virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins | |
| Saghazadeh et al. | Implications of Toll-like receptors in Ebola infection | |
| ATE468363T1 (de) | Verfahren zur behandlung von oberflächen | |
| Testoni et al. | Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes | |
| Cheng et al. | Differential transcription of fathead minnow immune-related genes following infection with frog virus 3, an emerging pathogen of ectothermic vertebrates | |
| RU2012145776A (ru) | Прогнозирование раннего вирусологического ответа при лечении заражения вирусом гепатита с | |
| Yang et al. | Immunopathogenesis of different emerging viral infections: evasion, fatal mechanism, and prevention | |
| RU2013109732A (ru) | Прогноз кинетики вируса гепатита с при лечении, исключающем интерферон | |
| Wong et al. | Evaluating antibody mediated protection against Alpha, Beta, and Delta SARS-CoV-2 variants of concern in K18-hACE2 transgenic mice | |
| RU2014124032A (ru) | Однонуклеотидный полиморфизм на хромосоме 15, который позволяет прогнозировать восприимчивость к лечению вируса гепатита с | |
| Eltahla et al. | Cross-genotypic examination of hepatitis C virus polymerase inhibitors reveals a novel mechanism of action for thumb binders | |
| WO2008045017A3 (en) | Sars and ebola inhibitors and use thereof, and methods for their discovery | |
| NZ599373A (en) | Biomarkers for predicting rapid response to hcv treatment | |
| WO2018075633A3 (en) | Compositions and methods for detecting or quantifying hepatitis c virus | |
| WO2014146048A3 (en) | Methods for determining viral sensitivity to viral inhibitors | |
| Kuri et al. | Interferon interplay helps tissue cells to cope with SARS-coronavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |